Our two lead programs are advancing through clinical development: VENT-02, a brain-penetrant NLRP3 inhibitor, has completed Phase 1 and VENT-03, a first-in-class cGAS inhibitor, is in Phase 1.
We are a clinical-stage biopharmaceutical company leveraging our machine learning-enabled ReSOLVE™ platform to advance a pipeline of novel medicines in immunology, inflammation, and neurology.